Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo (original) (raw)
Figure 6
Treatment of ob/ob mice with either FGF19 or FGF21 improves metabolic dysfunction.
In ob/ob mice neither FGF19 nor FGF21 were able to reduce body mass significantly; however, both treatment groups exhibited significant reductions in body mass accrual over the 7 day treatment period (A). Food intake was significantly reduced in the FGF19 treated mice while FGF21 treatment caused a trend to reduced caloric intake (B). No difference in adipose mass was observer following administration of either FGF19 or FGF21 (C) While the ob/ob mice showed significantly less profound effects on body mass and adiposity than was observed in the DIO group the glucose lowering following treatment with either FGF19 or FGF21 was still very significant suggesting possible partitioning of the effects of the endocrine FGFs (D).